Torres Mulieris are two skyscraper each with 44 floors, located in the Puerto Madero neighborhood in Buenos Aires, Argentina. Developed by Creaurban, a unit of the Macri Group, the two residential buildings were completed in 2009, and became the fifth-tallest buildings in Argentina.

During the past decade, Mulieris conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Mulieris" are "Alzheimer's Disease" (1 trials) and "Schizophrenia" (1 trials). Many other conditions were trialed in "Mulieris" in a lesser frequency.

Most popular intervention types in "Mulieris" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Antipshychotics (Standard of Care)" (1 trials), "Gantenerumab" (1 trials) and "RO4917838" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mulieris" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Mulieris". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Mulieris, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mulieris, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".